Susan Galbraith, AstraZeneca EVP of oncology R&D
After decade-plus of failures, AstraZeneca finally gets a win for storied immunotherapy (kind of)
Over the last decade, nearly every Big Pharma has invested hundreds of millions of dollars to develop its own PD-(L)1 drug.
By contrast, the other …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
